Advances in targeted therapies VI F C Breedveld, J R Kalden, and J S Smolen Ann Rheum Dis 2004; 63 (Supplement 2 ): ii1. doi:10.1136/ard.2004.028779 [Extract] [Full text] [PDF] [Request Permissions]
	Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, and P J Mease Ann Rheum Dis 2004; 63 (Supplement 2 ): ii2-ii12. doi:10.1136/ard.2004.029272 [Extract] [Full text] [PDF] [Request Permissions]
	Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues F Wolfe, K Michaud, and E M DeWitt Ann Rheum Dis 2004; 63 (Supplement 2 ): ii13-ii17. doi:10.1136/ard.2004.028530 [Abstract] [Full text] [PDF] [Request Permissions]
	Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection L H Calabrese, N Zein, and D Vassilopoulos Ann Rheum Dis 2004; 63 (Supplement 2 ): ii18-ii24. doi:10.1136/ard.2004.028209 [Abstract] [Full text] [PDF] [Request Permissions]
	Pharmacogenetics in the rheumatic diseases B N Cronstein Ann Rheum Dis 2004; 63 (Supplement 2 ): ii25-ii27. doi:10.1136/ard.2004.028217 [Extract] [Full text] [PDF] [Request Permissions]
	What precedes development of rheumatoid arthritis? L Klareskog, L Alfredsson, S Rantapää-Dahlqvist, E Berglin, P Stolt, and L Padyukov Ann Rheum Dis 2004; 63 (Supplement 2 ): ii28-ii31. doi:10.1136/ard.2004.028225 [Abstract] [Full text] [PDF] [Request Permissions]
	Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? T Pincus and T Sokka Ann Rheum Dis 2004; 63 (Supplement 2 ): ii32-ii39. doi:10.1136/ard.2004.028415 [Abstract] [Full text] [PDF] [Request Permissions]
	The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning G Stucki and A Cieza Ann Rheum Dis 2004; 63 (Supplement 2 ): ii40-ii45. doi:10.1136/ard.2004.028233 [Abstract] [Full text] [PDF] [Request Permissions]
	Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? S M Carty, N Snowden, and A J Silman Ann Rheum Dis 2004; 63 (Supplement 2 ): ii46-ii49. doi:10.1136/ard.2004.028241 [Extract] [Full text] [PDF] [Request Permissions]
	New issues in tuberculosis S H E Kaufmann Ann Rheum Dis 2004; 63 (Supplement 2 ): ii50-ii56. doi:10.1136/ard.2004.028258 [Abstract] [Full text] [PDF] [Request Permissions]
	Nuclear factor (NF)-B proteins: therapeutic targets I M Verma Ann Rheum Dis 2004; 63 (Supplement 2 ): ii57-ii61. doi:10.1136/ard.2004.028266 [Extract] [Full text] [PDF] [Request Permissions]
	Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs M Karin Ann Rheum Dis 2004; 63 (Supplement 2 ): ii62-ii64. doi:10.1136/ard.2004.028274 [Abstract] [Full text] [PDF] [Request Permissions]
	B cell signalling as therapeutic target R H Carter Ann Rheum Dis 2004; 63 (Supplement 2 ): ii65-ii66. doi:10.1136/ard.2004.028282 [Extract] [Full text] [PDF] [Request Permissions]
	Targeting the Jak/STAT pathway for immunosuppression J J O’Shea Ann Rheum Dis 2004; 63 (Supplement 2 ): ii67-ii71. doi:10.1136/ard.2004.028290 [Extract] [Full text] [PDF] [Request Permissions]
	DREAMing about arthritic pain H-Y M Cheng and J M Penninger Ann Rheum Dis 2004; 63 (Supplement 2 ): ii72-ii75. doi:10.1136/ard.2004.029942 [Abstract] [Full text] [PDF] [Request Permissions]
	A toll for T cell costimulation F Y Liew, M Komai-Koma, and D Xu Ann Rheum Dis 2004; 63 (Supplement 2 ): ii76-ii78. doi:10.1136/ard.2004.028308 [Extract] [Full text] [PDF] [Request Permissions]
	The utility of tumour necrosis factor blockade in orphan diseases E C Keystone Ann Rheum Dis 2004; 63 (Supplement 2 ): ii79-ii83. doi:10.1136/ard.2004.028498 [Abstract] [Full text] [PDF] [Request Permissions]
	Chemokines: role in inflammation and immune surveillance B Moser and K Willimann Ann Rheum Dis 2004; 63 (Supplement 2 ): ii84-ii89. doi:10.1136/ard.2004.028316 [Abstract] [Full text] [PDF] [Request Permissions]
	Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways C Ospelt, D Kyburz, M Pierer, R Seibl, M Kurowska, O Distler, M Neidhart, U Muller-Ladner, T Pap, R E Gay, and S Gay Ann Rheum Dis 2004; 63 (Supplement 2 ): ii90-ii91. doi:10.1136/ard.2004.028324 [Extract] [Full text] [PDF] [Request Permissions]
	Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease C D Buckley, A Filer, O Haworth, G Parsonage, and M Salmon Ann Rheum Dis 2004; 63 (Supplement 2 ): ii92-ii95. doi:10.1136/ard.2004.028332 [Abstract] [Full text] [PDF] [Request Permissions]
	Cell therapy for autoimmune diseases: does it have a future? A Radbruch and A Thiel Ann Rheum Dis 2004; 63 (Supplement 2 ): ii96-ii101. doi:10.1136/ard.2004.028340 [Abstract] [Full text] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.